Annexon Biosciences Reports Increased Q1 2025 Losses

Annexon Biosciences, Inc. ( (ANNX) ) has released its Q1 earnings. Here is a breakdown of the information Annexon Biosciences, Inc. presented to its investors.

Annexon Biosciences, Inc. is a biopharmaceutical company focused on developing therapies for neuroinflammatory diseases by targeting the classical complement pathway. In its latest earnings report for the first quarter of 2025, Annexon reported a net loss of $54.4 million, compared to a net loss of $25.2 million in the same period of 2024. The company’s operating expenses increased significantly, primarily due to higher research and development costs, which rose to $48.2 million from $21.0 million the previous year. Despite the losses, Annexon maintains a strong cash position with $263.7 million in cash and short-term investments, which the management believes will support operations for at least the next twelve months. Looking ahead, Annexon plans to continue its focus on advancing its clinical platform and achieving key development milestones to address unmet medical needs in complement-mediated diseases.